摘要
乙型肝炎病毒感染引起的慢性乙型肝炎仍是威胁我国人民生命健康的重要问题。当前治疗慢性乙型肝炎以口服恩替卡韦、替诺福韦和丙酚替诺福韦等高耐药屏障的一线核苷(酸)类似物为主,可强效抑制病毒复制,减少肝硬化和肝细胞癌的发生率。然而当前临床实践中,在启动治疗、监测疗效及判定停药等方面,均存在一定困难或争议。实现慢性乙型肝炎的“精准治疗”,很大程度上依赖于灵敏、特异的乙型肝炎病毒核酸检测技术及对其结果的科学解读。
Chronic hepatitis B(CHB)caused by hepatitis B virus(HBV)infection remains a major public health issue for the Chinese people.The current treatment regimen for CHB is mainly based on the oral administration of the first-line nucleos(t)ide analogs such as entecavir,tenofovir,and propofol tenofovir.These nucleos(t)ide analogs constitute a high drug-resistance barrier,strongly inhibit viral replication,and significantly reduce the incidence of liver cirrhosis and hepatocellular carcinoma.However,there are some difficulties or controversies in starting treatment,monitoring efficacy and determining drug withdrawal in current clinical practice.The realization of precision treatment of CHB largely depends on the sensitive and specific nucleic acid testing technology of HBV and the scientific interpretation of its results.
作者
杨瑞锋
陈红松
鲁凤民
YANG Rui-feng;CHEN Hong-song;LU Feng-min(Peking University People′s Hospital,Peking University Hepatology Institute,Beijing 100044,China)
出处
《中国临床新医学》
2021年第1期1-7,共7页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
国家“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项“十三五”计划项目(编号:2017ZX10302201)
国家自然科学基金资助项目(编号:81672013)。
关键词
乙型肝炎病毒
慢性乙型肝炎
核酸检测
Hepatitis B virus(HBV)
Chronic hepatitis B(CHB)
Nucleic acid testing
